Answers are grounded in this paper and cite their sources.
Background: New-onset refractory status epilepticus (NORSE) refers to the newly established concept of a disease characterized by refractory status epilepticus without an identifiable etiology.Recent reports have indicated the importance of immunotherapy for NORSE.Case Report: A 37-year-old man with no past history of epilepsy was admitted for a presenting complaint of confusion.He was treated with acyclovir and anti-epileptic drug (AED) for presumed herpes encephalitis.However, he developed generalized tonic-clonic seizures on day 6 of admission that worsened despite treatment with multiple AEDs.NORSE was considered to be a probable diagnosis and immunotherapy with methylprednisolone and immunoglobulin was scheduled.However, persistent seizure activity was observed on the electroencephalogram after the completion of initial immunotherapy.Subsequently, rituximab was administered for 4 weeks.He eventually regained consciousness and was able to resume social activity.Conclusion: Our patient exhibited a favorable outcome with early-intensive immunotherapy and subsequent rituximab treatment for NORSE.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: